Skip to content

Study · Not a test of the peptide alone · 2025

3 results

Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome.

De Sio V, Gragnano F, Capolongo A, Guarnaccia N, Maddaluna P, Acerbo V, Galli M, Berteotti M, Sperlongano S, Cesaro A, Moscarella E, Pelliccia F and 9 more

Show all authors

Patti G, Antonucci E, Cirillo P, Pignatelli P, Palareti G, Pengo V, Gresele P, Marcucci R, Calabrò P

International journal of cardiology29 Jan 2025Cited by 12 (Europe PMC)

PMID39890028 (opens in a new tab)DOI10.1016/j.ijcard.2025.133028 (opens in a new tab)PepBankPUB-39890028
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

AimsSemaglutide has been shown to reduce cardiovascular events in non-diabetic patients with preexisting cardiovascular disease and overweight/obesity in the SELECT trial. Data on the applicability of these results to clinical practice are limited. We evaluated the eligibility for and practical implications of semaglutide in overweight/obese non-diabetic patients with recent acute coronary syndrome (ACS) from a contemporary real-world registry.MethodsPatients from the multicenter START-ANTIPLATELET registry (NCT02219984) were stratified to investigate the proportion of patients eligible for semaglutide >60 days after discharge for ACS (post-acute phase), according to the SELECT trial eligibility criteria: age ≥ 45 years; body mass index ≥27 kg/m2; history of myocardial infarction (MI), stroke, or peripheral artery disease; no diabetes. Major adverse cardiovascular events (MACE), defined as a composite of all-cause death, MI, target vessel revascularization, or stroke, and net adverse clinical events (NACE), a composite of all-cause death, MI, stroke, or major bleeding, were assessed at 1-year follow-up.ResultsThe study population comprised 2940 consecutive ACS patients. At 60 days after discharge, 807 patients (27.4 %) met the SELECT eligibility criteria (SELECT-like group) and 2133 patients were ineligible (not-eligible group). At 1 year, incidence of MACE (4.6 % vs. 8.2 %; p = 0.004) and NACE (3.6 % vs. 7.6 %; p < 0.001) was lower in the SELECT-like group compared to the not-eligible group.ConclusionsIn a contemporary real-world registry, a significant proportion of post-ACS patients were eligible for semaglutide according to the SELECT trial criteria. Future studies are needed to evaluate the potential implications of semaglutide for secondary prevention.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneObservational studyOther

    In 2940 patients with recent acute coronary syndrome, 807 (27.4%) met the SELECT eligibility criteria for semaglutide at 60 days after discharge.

    In plain wordsIn patients after a heart attack or similar event, about 27% would have qualified for semaglutide under the SELECT trial rules.

    Peptide
    Semaglutide
    Outcome
    Not applicableProportion of post-ACS patients eligible for semaglutide by SELECT criteria
    Study

    n = 2,940

    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Eligible patients
    27.4%
    SELECT-like group

    Source sentences

    Summary
    At 60 days after discharge, 807 patients (27.4 %) met the SELECT eligibility criteria (SELECT-like group) and 2133 patients were ineligible (not-eligible group).
    1 context sentence
    Summary · context
    We evaluated the eligibility for and practical implications of semaglutide in overweight/obese non-diabetic patients with recent acute coronary syndrome (ACS) from a contemporary real-world registry.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneObservational studyOther

    In patients with recent ACS, 1-year MACE was lower in the SELECT-like group than in the not-eligible group (4.6% versus 8.2%); no semaglutide was given.

    In plain wordsIn patients after a heart event, those who fit the SELECT rules had fewer major heart events than those who did not; none took semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseMACE at 1 year, SELECT-like versus not-eligible group
    Study

    n = 2,940

    Comparator
    Not-eligible group
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    MACE
    4.6%
    SELECT-like
    MACE
    8.2%
    not eligible

    Source sentences

    Summary
    At 1 year, incidence of MACE (4.6 % vs. 8.2 %; p = 0.004)
    1 context sentence
    Summary · context
    We evaluated the eligibility for and practical implications of semaglutide in overweight/obese non-diabetic patients with recent acute coronary syndrome (ACS) from a contemporary real-world registry.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Semaglutide aloneObservational studyOther

    In patients with recent ACS, 1-year NACE was lower in the SELECT-like group than in the not-eligible group (3.6% versus 7.6%); no semaglutide was given.

    In plain wordsIn patients after a heart event, those who fit the SELECT rules had fewer major adverse events than those who did not; none took semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseNACE at 1 year, SELECT-like versus not-eligible group
    Study

    n = 2,940

    Comparator
    Not-eligible group
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    NACE
    3.6%
    SELECT-like
    NACE
    7.6%
    not eligible

    Source sentences

    Summary
    and NACE (3.6 % vs. 7.6 %; p < 0.001) was lower in the SELECT-like group compared to the not-eligible group.
    1 context sentence
    Summary · context
    We evaluated the eligibility for and practical implications of semaglutide in overweight/obese non-diabetic patients with recent acute coronary syndrome (ACS) from a contemporary real-world registry.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.